MEREO BIOPHARMA GROUP PLC Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of -GBP 784.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-28.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2023-03-28
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2022-12-31 | -784.00K GBP 20-F · filed 2023-03-28 |
| 2021-12-31 | -692.00K GBP 20-F · filed 2023-03-28 |
| 2020-12-31 | 37.02M GBP 20-F · filed 2022-03-31 |
| 2019-12-31 | -3.95M GBP 20-F · filed 2021-03-31 |
| 2018-12-31 | -2.08M GBP 20-F · filed 2020-06-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |